Visit our Covid-19 microsite for the latest coronavirus news, analysis and updates Moleculin Biotech has partnered with the University of Texas Medical Branch at Galveston (UTMB) to test its molecular inhibitors, including WP1122, to treat different viruses, including coronavirus.
UTMB’s Center for Biodefense and Emerging Infectious Diseases works with Galveston National Laboratory, the US Department of Defense and the US Centers for Disease Control & Prevention, among other partners.
Under the deal, Moleculin will supply WP1122 and related inhibitors, as well as provide technical support. UTMB will start assessing these candidates against different viral disease models, including Covid-19, in alliance with UTMB Center for Biodefense and